Nanobiotix s.a.NBTX.US Overview

US StockHealthcare

(No presentation for NBTX)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

NBTX Overall Performance

NBTX AI Analysis & Strategy

NBTX Recent Performance

1.25%

Nanobiotix s.a.

0.81%

Avg of Sector

-1.14%

S&P500

NBTX PowerScanner

NBTX Key Information

NBTX Valuation Metrics

NBTX Earnings Table

NBTX Profile

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.